TICKERNERD
Menu
IONSIONSHealthcare · Biotechnology

IONS Stock Forecast: Ionis Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$44
+1.15% on the day

The 23 Wall Street analysts covering Ionis Pharmaceuticals, Inc. hold a median 12-month price target of $85 — +93.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 6 Oct 2026 — in the lower half.

Market cap
$7.2B
Ticker Nerd rank
42 / 100
Median analyst target
$85
Analysts covering
23
Revenue$267.9M−40.7% y/y
Operating income−$102.3M
Net income−$114.6M
Free cash flow$547.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.1%
1M
−24.3%
YTD
−44.4%
1Y
−36.3%
From 52W high
−49.1%
From 52W low
+1.1%
$44
$87
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IONS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ionis Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
42 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
84
Quality
79
Value
71
Revisions
68
Momentum
42
Accruals
37
Growth
28
Issuance
18
Size
18

Volatility (84): The share price has been relatively steady.

Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.

Size (18): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IONS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IONS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100Jan 26Apr 26Jul 26Oct 26IONSHigh $105Median $85Low $54

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says23 analysts
18 Buy5 Hold0 Sell
Low $54Median $85High $105

The green dot is the last close — the median target sits +93.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 8 moved it down.

DateFirmActionRatingTarget
24 Sept 2026HC Wainwright & Co.ReiteratesBuy$100
22 Sept 2026JP MorganMaintainsOverweight$76 → $70
15 Sept 2026GuggenheimMaintainsBuy$89 → $80
15 Sept 2026GuggenheimMaintainsBuy—
9 Sept 2026BarclaysMaintainsOverweight$90 → $85
9 Sept 2026BarclaysMaintainsOverweight—
8 Sept 2026BMO CapitalMaintainsMarket Perform—
8 Sept 2026BMO CapitalMaintainsMarket Perform$61 → $54
8 Sept 2026Canaccord GenuityMaintainsBuy$95 → $85
8 Sept 2026Canaccord GenuityMaintainsBuy—
8 Sept 2026Goldman SachsMaintainsNeutral$69 → $56
8 Sept 2026Goldman SachsMaintainsNeutral—
8 Sept 2026HC Wainwright & Co.MaintainsBuy$115 → $100
8 Sept 2026HC Wainwright & Co.MaintainsBuy—
8 Sept 2026Morgan StanleyMaintainsOverweight—
8 Sept 2026Morgan StanleyMaintainsOverweight$110 → $104
4 Sept 2026BMO CapitalMaintainsMarket Perform$60 → $61
4 Sept 2026BMO CapitalMaintainsMarket Perform—
4 Sept 2026HC Wainwright & Co.ReiteratesBuy$115
4 Sept 2026HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IONS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IONS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Ionis Pharmaceuticals, Inc. returned −36.3% against +17.3% for the S&P 500, dividends included.

IONS vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Jan 26Apr 26Jul 26Oct 26IONSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IONS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

Ionis Pharmaceuticals, Inc. (IONS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−18.3×

Cheaper than 96% of US stocks

Price / sales
8.3×

Cheaper than 16% of US stocks

Price / book
16.4×

Cheaper than 6% of US stocks

EV / EBITDA
−12.6×

Cheaper than 86% of US stocks

Growth & margins
Revenue growth (YoY)
−40.7%

Higher than 7% of US stocks

Earnings growth (YoY)
—
Gross margin
99.0%

Higher than 99% of US stocks

Operating margin
−38.2%

Higher than 18% of US stocks

Net margin
−64.7%

Higher than 8% of US stocks

Returns & dividend
Return on equity
−105.5%

Higher than 13% of US stocks

Return on assets
−12.4%

Higher than 25% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Ionis Pharmaceuticals, Inc. (IONS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Ionis Pharmaceuticals, Inc. has a market value of $7.2B and an enterprise value of $7.3B.

  • Revenue in the twelve months to 30 June 2026: $874.1M. The latest quarter shrank 40.7% year on year.

  • Net income over the same four quarters: −$565.2M, a −64.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.46.

  • Free cash flow in the twelve months to 30 June 2026: −$567.5M.

  • Shares outstanding: 165.9M.

  • Trailing P/E: −18.3×; forward P/E: −39.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Ionis Pharmaceuticals, Inc. employs 1,480 people — $591K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

IONS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IONSIonis Pharmaceuticals, Inc.$7.2B
42
PRAXPraxis Precision Medicines, Inc.$7.7B
41
SYRESpyre Therapeutics, Inc.$6.9B
46
CAICaris Life Sciences, Inc.$7.8B
36
IMVTImmunovant, Inc.$6.5B
38
TGTXTG Therapeutics, Inc.$8.3B
69
CYTKCytokinetics, Inc.$8.5B
48

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ionis Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IONS news & analysis

4 RNA Therapeutics Stocks Leading the Next Wave of Innovation

Zacks Investment Research · 28 Sept 2026positive

Zacks Investment Research highlighted Ionis Pharmaceuticals among four RNA therapeutics stocks—alongside Alnylam, Wave Life Sciences, and Arcturus—that are advancing innovative treatments targeting a range of diseases as the field gains momentum.

Why it matters — The piece positions Ionis as a leading innovator within a growing and increasingly competitive RNA therapeutics space, reinforcing its relevance to investors tracking the sector.

Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs

Zacks Investment Research · 23 Sept 2026positive

Ionis Pharmaceuticals reported positive late-stage results for two partnered drugs: ulefnersen met its endpoint in an ALS trial, and sefaxersen reduced proteinuria in a phase III study.

Why it matters — Positive phase III outcomes for these partnered programs could support the progress and value of Ionis' pipeline and collaborations.

Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease

Benzinga · 23 Sept 2026neutral

Ionis and its licensing partner Roche shared prespecified interim outcomes from their ongoing Phase 3 IMAgINATION trial of sefaxersen, an investigational RNA-targeted therapy for adults with primary IgA nephropathy. The results relate to the first RNA-targeted therapy for this autoimmune kidney disease.

Why it matters — The interim Phase 3 data for sefaxersen is a key development milestone for Ionis' investigational kidney disease program and its partnership with Roche.

Ionis announces positive interim data from partner Roche's Phase 3 IMAgINATION study in IgA nephropathy (IgAN)

Business Wire · 23 Sept 2026positive

Ionis and partner Roche announced positive prespecified interim results from the Phase 3 IMAgINATION study of sefaxersen in adults with primary IgA nephropathy. The study met its primary endpoint, with sefaxersen achieving statistically significant and clinically meaningful improvements in proteinuria reduction versus placebo at 37 weeks.

Why it matters — This interim result supports the clinical progress of Ionis' partnered investigational candidate sefaxersen in IgA nephropathy.

Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study

Reuters · 22 Sept 2026positive

Otsuka Pharmaceutical and Ionis Pharmaceuticals announced that their experimental drug met the main goal of a late-stage study in patients with a rare inherited form of amyotrophic lateral sclerosis (ALS).

Why it matters — A successful late-stage readout for Ionis' experimental ALS drug marks a key clinical milestone that could advance the candidate's development for a rare inherited form of the disease.

FAQ

Frequently asked questions about IONS stock

What is the IONS stock price forecast for 2026-2027?

The 23 Wall Street analysts covering Ionis Pharmaceuticals, Inc. have a median 12-month price target of $85, with estimates ranging from $54 to $105. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IONS stock a buy right now?

Of the 23 analysts covering Ionis Pharmaceuticals, Inc., 18 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ionis Pharmaceuticals, Inc. 42 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IONS?

As at 6 Oct 2026, Ionis Pharmaceuticals, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (84 of 100).

Will IONS stock go up?

No one can know that. What the data says: the median 12-month target from 23 analysts implies +93.2% from the last close, and Ticker Nerd's factor model ranks Ionis Pharmaceuticals, Inc. 42 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IONS stock forecast for 2030?

No analyst covering Ionis Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IONS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $54 to $105 over the next 12 months.

How has IONS stock performed over the past year?

Ionis Pharmaceuticals, Inc. returned -36.3% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ionis Pharmaceuticals, Inc. do?

Ionis Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on discovering and developing RNA-targeted medicines.

What is the latest news on IONS?

The most recent item we track (Zacks Investment Research, 28 Sept 2026): "4 RNA Therapeutics Stocks Leading the Next Wave of Innovation". Zacks Investment Research highlighted Ionis Pharmaceuticals among four RNA therapeutics stocks—alongside Alnylam, Wave Life Sciences, and Arcturus—that are advancing innovative treatments targeting a range of diseases as the field gains momentum.

Company

About Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on discovering and developing RNA-targeted medicines. Using its proprietary antisense technology, Ionis creates therapies designed to modulate gene expression and address serious diseases, particularly in neurology and cardiometabolic care, as well as other high-need therapeutic areas. The company currently markets several medicines for conditions such as spinal muscular atrophy, hereditary amyloidosis, amyotrophic lateral sclerosis, and certain rare cardiovascular and metabolic disorders. Ionis also maintains an active pipeline of investigational programs and collaborates with pharmaceutical partners to expand the reach of its platform. Headquartered in Carlsbad, California, Ionis Pharmaceuticals plays a significant role in the biotechnology market as a leading developer of RNA-based therapeutics.

CEO Dr. Brett P. Monia Ph.D. · 1,480 employees · United States · https://www.ionis.com